Inhibitor Therapeutics (INTI) Short Interest Ratio & Short Volume

Short interest is the volume of Inhibitor Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 25,800 shares of INTI short. Learn More on Inhibitor Therapeutics' current short interest.

Inhibitor Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 25,800 shares, an increase of 218.5% from the previous total of 8,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Inhibitor Therapeutics: Prelude Therapeutics Incorporated (3.60%), Quince Therapeutics, Inc. (3.12%), Rani Therapeutics Holdings, Inc. (10.31%), Spero Therapeutics, Inc. (1.15%), Barinthus Biotherapeutics plc (0.14%), Acrivon Therapeutics, Inc. (6.39%), Lantern Pharma Inc. (3.17%), Aligos Therapeutics, Inc. (20.79%), FibroBiologics, Inc. (5.36%), Alterity Therapeutics Limited (0.35%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks.

Short selling INTI is an investing strategy that aims to generate trading profit from Inhibitor Therapeutics as its price is falling. INTI shares are trading up $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Inhibitor Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of INTI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INTI, twice per month. The most recent reporting period available is April, 30 2025.